Roundview Capital’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.58M | Sell |
7,151
-48
| -0.7% | -$48.7K | 0.41% | 58 |
|
|
2025
Q4 | $7.74M | Buy |
7,199
+935
| +15% | +$894K | 0.48% | 48 |
|
|
2025
Q3 | $4.78M | Buy |
6,264
+614
| +11% | +$457K | 0.3% | 78 |
|
|
2025
Q2 | $4.4M | Buy |
5,650
+933
| +20% | +$725K | 0.29% | 78 |
|
|
2025
Q1 | $3.9M | Buy |
4,717
+309
| +7% | +$257K | 0.28% | 84 |
|
|
2024
Q4 | $3.4M | Buy |
4,408
+963
| +28% | +$797K | 0.24% | 97 |
|
|
2024
Q3 | $3.05M | Buy |
3,445
+91
| +3% | +$81.8K | 0.22% | 98 |
|
|
2024
Q2 | $3.04M | Buy |
3,354
+184
| +6% | +$147K | 0.24% | 97 |
|
|
2024
Q1 | $2.47M | Buy |
3,170
+337
| +12% | +$240K | 0.2% | 114 |
|
|
2023
Q4 | $1.65M | Buy |
2,833
+505
| +22% | +$295K | 0.15% | 138 |
|
|
2023
Q3 | $1.25M | Buy |
2,328
+41
| +2% | +$21.1K | 0.13% | 160 |
|
|
2023
Q2 | $1.07M | Sell |
2,287
-80
| -3% | -$33.5K | 0.1% | 184 |
|
|
2023
Q1 | $813K | Sell |
2,367
-397
| -14% | -$134K | 0.09% | 207 |
|
|
2022
Q4 | $1.01M | Buy |
2,764
+163
| +6% | +$57.8K | 0.12% | 178 |
|
|
2022
Q3 | $841K | Buy |
2,601
+327
| +14% | +$104K | 0.11% | 177 |
|
|
2022
Q2 | $737K | Buy |
2,274
+218
| +11% | +$65.4K | 0.09% | 197 |
|
|
2022
Q1 | $589K | Buy |
2,056
+53
| +3% | +$13.6K | 0.06% | 217 |
|
|
2021
Q4 | $553K | Hold |
2,003
| – | – | 0.06% | 227 |
|
|
2021
Q3 | $463K | Buy |
2,003
+400
| +25% | +$98.7K | 0.05% | 234 |
|
|
2021
Q2 | $368K | Hold |
1,603
| – | – | 0.04% | 239 |
|
|
2021
Q1 | $299K | Buy |
1,603
+300
| +23% | +$58.7K | 0.04% | 244 |
|
|
2020
Q4 | $220K | Buy |
+1,303
| New | +$195K | 0.03% | 237 |
|
|
2020
Q3 | – | Sell |
-1,287
| Closed | -$211K | – | 242 |
|
|
2020
Q2 | $211K | Buy |
+1,287
| New | +$198K | 0.04% | 230 |
|
|
2020
Q1 | – | Sell |
-7,548
| Closed | -$992K | – | 226 |
|
|
2019
Q4 | $992K | Buy |
7,548
+2,330
| +45% | +$270K | 0.19% | 139 |
|
|
2019
Q3 | $584K | Hold |
5,218
| – | – | 0.13% | 170 |
|
|
2019
Q2 | $578K | Sell |
5,218
-450
| -8% | -$53K | 0.13% | 164 |
|
|
2019
Q1 | $735K | Sell |
5,668
-235
| -4% | -$28.6K | 0.17% | 143 |
|
|
2018
Q4 | $683K | Buy |
5,903
+401
| +7% | +$44.8K | 0.19% | 132 |
|
|
2018
Q3 | $590K | Hold |
5,502
| – | – | 0.15% | 154 |
|
|
2018
Q2 | $469K | Buy |
+5,502
| New | +$452K | 0.12% | 169 |
|
Other funds holding LLY
VCM
VPM
Roundview Capital's LLY Position: Q1 2026 in Review
Roundview Capital reduced its Eli Lilly (LLY) stake by 0.67% in Q1 2026, selling an estimated $48.7K and leaving 7,151 shares worth $6.58M. The position accounts for 0.41% of the portfolio, ranked #58.
Roundview Capital first reported a position in LLY in Q2 2018 and has held it in 30 quarters since. The position peaked at $7.74M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Roundview Capital held 7,151 shares of Eli Lilly worth $6.58M as of Q1 2026.
- Roundview Capital sold 48 Eli Lilly shares in Q1 2026, an estimated $48.7K.
- Eli Lilly made up 0.41% of Roundview Capital's portfolio in Q1 2026, its #58 holding.
- Roundview Capital first reported a position in Eli Lilly in Q2 2018 and has held it in 30 quarters since.
- Roundview Capital's Eli Lilly position peaked at $7.74M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Roundview Capital's 13F filing for Q1 2026, filed 8 May 2026.